Vascular Solutions, Inc. operates as a medical device company that focuses on developing clinical solutions for coronary and peripheral vascular procedures.

According to the Complaint, on December 1, 2016, Vascular Solutions’ Board of Directors (the “Board” or “Individual Defendants”) caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, shareholders of Vascular Solutions will receive $56.00 per share in cash.

On January 18, 2017, Defendants filed a Proxy Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on February 17, 2017.